Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma

Hideya Ohnishi, Takashi Morisaki, Eishi Baba, Mitsunari Nakamura, Syoichi Inaba, Hideo Kuroki, Kotaro Matsumoto, Mitsuo Katano

研究成果: ジャーナルへの寄稿記事

11 引用 (Scopus)

抄録

We performed continuous dendritic cells (DCs) vaccination to treat a patient with chemotherapy-resistant recurrent rectal carcinoma and lung and bone metastases. A patient has received a total of 66 DC vaccinations at 14-day intervals for 3 years until his death. Necrotic whole tumor cells (WTC) were selected as the tumor-associated antigen source because they showed a greater capacity for DC maturation and interleukin-12 secretion than both necrotic tumor lysate alone and necrotic tumor cell fragment alone. After the sixth vaccination, both skin test and interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) response by peripheral blood T-cells to WTC-pulsed DCs were positive. Importantly, T-cell responses were positive towards DCs pulsed with several synthetic peptides including Carcinoembryonic antigen (CEA), Melanoma associated antigen (MAGE)1 and MAGE3. A biopsy specimen collected from the pelvic bone metastasis after the 6th vaccination showed marked necrotic change of the carcinoma cells, with many infiltrating mononuclear cells. The patient did not show any particular adverse reactions to vaccination such as autoimmune phenomena. Our experience of this case suggests that continuous long-term vaccination with autologous WTC-pulsed DCs can elicit in vivo T-cell response against multiple tumor-associated antigens and induce tumor regression in disease that has proven resistant to intensive chemo- or radiation therapy.

元の言語英語
ページ(範囲)3995-4005
ページ数11
ジャーナルAnticancer Research
31
発行部数11
出版物ステータス出版済み - 11 1 2011

Fingerprint

Active Immunotherapy
Dendritic Cells
Vaccination
Carcinoma
Neoplasms
Neoplasm Antigens
T-Lymphocytes
Pelvic Bones
Neoplasm Metastasis
Melanoma-Specific Antigens
Carcinoembryonic Antigen
Interleukin-12
Skin Tests
Interferons
Blood Cells
Radiotherapy
Biopsy
Bone and Bones
Drug Therapy
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma. / Ohnishi, Hideya; Morisaki, Takashi; Baba, Eishi; Nakamura, Mitsunari; Inaba, Syoichi; Kuroki, Hideo; Matsumoto, Kotaro; Katano, Mitsuo.

:: Anticancer Research, 巻 31, 番号 11, 01.11.2011, p. 3995-4005.

研究成果: ジャーナルへの寄稿記事

Ohnishi, H, Morisaki, T, Baba, E, Nakamura, M, Inaba, S, Kuroki, H, Matsumoto, K & Katano, M 2011, 'Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma', Anticancer Research, 巻. 31, 番号 11, pp. 3995-4005.
Ohnishi, Hideya ; Morisaki, Takashi ; Baba, Eishi ; Nakamura, Mitsunari ; Inaba, Syoichi ; Kuroki, Hideo ; Matsumoto, Kotaro ; Katano, Mitsuo. / Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma. :: Anticancer Research. 2011 ; 巻 31, 番号 11. pp. 3995-4005.
@article{49c0116e1d73439fa02b4926e9dadb44,
title = "Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma",
abstract = "We performed continuous dendritic cells (DCs) vaccination to treat a patient with chemotherapy-resistant recurrent rectal carcinoma and lung and bone metastases. A patient has received a total of 66 DC vaccinations at 14-day intervals for 3 years until his death. Necrotic whole tumor cells (WTC) were selected as the tumor-associated antigen source because they showed a greater capacity for DC maturation and interleukin-12 secretion than both necrotic tumor lysate alone and necrotic tumor cell fragment alone. After the sixth vaccination, both skin test and interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) response by peripheral blood T-cells to WTC-pulsed DCs were positive. Importantly, T-cell responses were positive towards DCs pulsed with several synthetic peptides including Carcinoembryonic antigen (CEA), Melanoma associated antigen (MAGE)1 and MAGE3. A biopsy specimen collected from the pelvic bone metastasis after the 6th vaccination showed marked necrotic change of the carcinoma cells, with many infiltrating mononuclear cells. The patient did not show any particular adverse reactions to vaccination such as autoimmune phenomena. Our experience of this case suggests that continuous long-term vaccination with autologous WTC-pulsed DCs can elicit in vivo T-cell response against multiple tumor-associated antigens and induce tumor regression in disease that has proven resistant to intensive chemo- or radiation therapy.",
author = "Hideya Ohnishi and Takashi Morisaki and Eishi Baba and Mitsunari Nakamura and Syoichi Inaba and Hideo Kuroki and Kotaro Matsumoto and Mitsuo Katano",
year = "2011",
month = "11",
day = "1",
language = "English",
volume = "31",
pages = "3995--4005",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma

AU - Ohnishi, Hideya

AU - Morisaki, Takashi

AU - Baba, Eishi

AU - Nakamura, Mitsunari

AU - Inaba, Syoichi

AU - Kuroki, Hideo

AU - Matsumoto, Kotaro

AU - Katano, Mitsuo

PY - 2011/11/1

Y1 - 2011/11/1

N2 - We performed continuous dendritic cells (DCs) vaccination to treat a patient with chemotherapy-resistant recurrent rectal carcinoma and lung and bone metastases. A patient has received a total of 66 DC vaccinations at 14-day intervals for 3 years until his death. Necrotic whole tumor cells (WTC) were selected as the tumor-associated antigen source because they showed a greater capacity for DC maturation and interleukin-12 secretion than both necrotic tumor lysate alone and necrotic tumor cell fragment alone. After the sixth vaccination, both skin test and interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) response by peripheral blood T-cells to WTC-pulsed DCs were positive. Importantly, T-cell responses were positive towards DCs pulsed with several synthetic peptides including Carcinoembryonic antigen (CEA), Melanoma associated antigen (MAGE)1 and MAGE3. A biopsy specimen collected from the pelvic bone metastasis after the 6th vaccination showed marked necrotic change of the carcinoma cells, with many infiltrating mononuclear cells. The patient did not show any particular adverse reactions to vaccination such as autoimmune phenomena. Our experience of this case suggests that continuous long-term vaccination with autologous WTC-pulsed DCs can elicit in vivo T-cell response against multiple tumor-associated antigens and induce tumor regression in disease that has proven resistant to intensive chemo- or radiation therapy.

AB - We performed continuous dendritic cells (DCs) vaccination to treat a patient with chemotherapy-resistant recurrent rectal carcinoma and lung and bone metastases. A patient has received a total of 66 DC vaccinations at 14-day intervals for 3 years until his death. Necrotic whole tumor cells (WTC) were selected as the tumor-associated antigen source because they showed a greater capacity for DC maturation and interleukin-12 secretion than both necrotic tumor lysate alone and necrotic tumor cell fragment alone. After the sixth vaccination, both skin test and interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) response by peripheral blood T-cells to WTC-pulsed DCs were positive. Importantly, T-cell responses were positive towards DCs pulsed with several synthetic peptides including Carcinoembryonic antigen (CEA), Melanoma associated antigen (MAGE)1 and MAGE3. A biopsy specimen collected from the pelvic bone metastasis after the 6th vaccination showed marked necrotic change of the carcinoma cells, with many infiltrating mononuclear cells. The patient did not show any particular adverse reactions to vaccination such as autoimmune phenomena. Our experience of this case suggests that continuous long-term vaccination with autologous WTC-pulsed DCs can elicit in vivo T-cell response against multiple tumor-associated antigens and induce tumor regression in disease that has proven resistant to intensive chemo- or radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=83055195401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055195401&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 3995

EP - 4005

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -